GEN Exclusives

More »

GEN News Highlights

More »
Nov 8, 2011

First Phase III Study with Targacept and AstraZeneca’s Adjunctive Antidepressant Misses Primary Endpoint

  • The first Phase III study evaluating Targacept and partner AstraZeneca’s nicotinic channel modulator TC-5214 failed to meet its primary endpoint. The Renaissance 3 study was evaluating use of TC-5214 as an adjunct to antidepressant therapy in patients with major depressive disorder (MDD) who don’t respond adequately to initial antidepressant treatment. Data from the trial showed that adding TC-5214 to antidepressant treatment failed to result in a change on the Montgomery–Asberg Depression Rating Scale (MADRS) after eight weeks of treatment.

    The European Renaissance 3 study included 624 patients with MDD who initially received one of seven SSRI or SNRI antidepressants on an open-label basis for eight weeks. Two-hundred ninety-five patients who didn’t respond to treatment were randomized to a double-blind phase and received either a physician-prescribed flexible dose of TC-5214 or placebo, while continuing on SSRI or SNRI therapy for another eight weeks.

    The Renaissance program will include another flexible-dose study (Renaissance 2) and two fixed-dose studies (Renaissance 4 and 5) that will evaluate the efficacy and tolerability of TC-5214 as an adjunct to SSRI/SNRI therapy. A fifth study, Renaissance 7, is a long-term safety study evaluating the adjunctive use of TC-5214 for a year. In February the firms started a 350-patient Phase IIb study investigating TC-5214 as a “switch” monotherapy for MDD patients who don’t respond adequately to initial antidepressant therapy. Patients who do not respond adequately to open-label treatment with one of six commonly used SSRI or SNRI antidepressants will be switched to receive either one of two fixed doses of TC-5214, the active control duloxetine, or placebo, for eight weeks.

    AstraZeneca and Targacept inked their global development and commercialization deal for TC-5214 back in December 2001. Under terms of the agreement Targacept received a $200 million up-front payment and could earn another $540 million in development, regulatory, and commercial milestones, plus up to $500 million in sales milestones. The firm has retained an option for co-promotion of TC-5214 to a limited target physician audience in the U.S.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »